Matthew Dankner
Impact in
- Oncology top 10%
- Colorectal Cancer Treatments and Studies
- Cancer Immunotherapy and Biomarkers
- Pathology and Forensic Medicine top 10%
- Cancer Mechanisms and Therapy
Papers in
- Oncology 12
- Colorectal Cancer Treatments and Studies 4
- HER2/EGFR in Cancer Research 2
-
- Melanoma and MAPK Pathways 9
- Co-authors
- April A. N. Rose (14 shared papers)Peter M. Siegel (11 shared papers)Shivshankari Rajkumar (4 shared papers)Ian R. Watson (4 shared papers)Scott D. Gray‐Owen (1 shared paper)Yu‐Hwa Huang (1 shared paper)Nicole Beauchemin (1 shared paper)Richard S. Blumberg (1 shared paper)
- Journals
- Neuro-Oncology Advances (2 papers)Clinical and investigative medicine (2 papers)JCO Precision Oncology (2 papers)Journal of Clinical Oncology (2 papers)Cancers (2 papers)
- Partner nations
- CanadaUnited StatesJapan
In The Last Decade
Matthew Dankner
27 papers receiving 778 citations
Matthew Dankner's Hit Papers
Peers
Comparison fields: 5 of 67
- Oncology 328
- Pathology and Forensic Medicine 123
- Cancer Research 102
- Pulmonary and Respiratory Medicine 200
- Molecular Biology 350
Countries citing papers authored by Matthew Dankner
This map shows the geographic impact of Matthew Dankner's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Matthew Dankner with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Matthew Dankner more than expected).
Fields of papers citing papers by Matthew Dankner
This network shows the impact of papers produced by Matthew Dankner. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Matthew Dankner. The network helps show where Matthew Dankner may publish in the future.
Co-authors
The 25 scholars most cited alongside Matthew Dankner, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 29 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Classifying BRAF alterations in cancer: new rational therapeutic strategies for actionable mutations Hit paper breakdown → | 2018 | 365 |
| 2 | Neoadjuvant Chemoimmunotherapy for NSCLC Hit paper breakdown → | 2024 | 106 |
| 3 | 2017 | 96 | |
| 4 | 2018 | 47 | |
| 5 | 2023 | 22 | |
| 6 | 2024 | 20 | |
| 7 | 2018 | 18 | |
| 8 | 2021 | 17 | |
| 9 | 2022 | 16 | |
| 10 | 2022 | 16 | |
| 11 | 2018 | 15 | |
| 12 | 2020 | 13 | |
| 13 | 2019 | 9 | |
| 14 | 2024 | 7 | |
| 15 | 2024 | 6 | |
| 16 | 2024 | 3 | |
| 17 | 2019 | 3 | |
| 18 | 2024 | 3 | |
| 19 | 2021 | 2 | |
| 20 | 2020 | 2 |
About Matthew Dankner
Matthew Dankner is a scholar working on Oncology, Molecular Biology, Pulmonary and Respiratory Medicine, Organic Chemistry and Genetics, having authored 29 papers that have together received 796 indexed citations. Recurring topics across this work include Melanoma and MAPK Pathways (9 papers), Brain Metastases and Treatment (6 papers), Lung Cancer Treatments and Mutations (5 papers), Colorectal Cancer Treatments and Studies (4 papers), Computational Drug Discovery Methods (2 papers), HER2/EGFR in Cancer Research (2 papers), Synthesis and biological activity (2 papers) and Cancer Mechanisms and Therapy (2 papers). The work is most often cited by research in Oncology (328 citations), Pathology and Forensic Medicine (123 citations), Cancer Research (102 citations), Pulmonary and Respiratory Medicine (200 citations) and Molecular Biology (350 citations). Matthew Dankner has collaborated with scholars based in Canada, United States and Japan. Frequent co-authors include April A. N. Rose, Peter M. Siegel, Shivshankari Rajkumar, Ian R. Watson, Scott D. Gray‐Owen, Yu‐Hwa Huang, Nicole Beauchemin, Richard S. Blumberg, Kevin Petrecca and Jonathan Spicer. Their work appears in journals such as Neuro-Oncology Advances, Clinical and investigative medicine, JCO Precision Oncology, Journal of Clinical Oncology and Cancers.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.